paroxetine has been researched along with Cardiac Hypertrophy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, L; Gao, D; Li, W; Li, X; Liu, J; Niu, X | 1 |
| Cai, J; Huang, Y; Jiang, W; Lu, Y; Peng, L; Sun, X; Wen, G; Wu, J; Yuan, H; Zhou, M | 1 |
| Fukunaga, K; Tagashira, H | 1 |
1 review(s) available for paroxetine and Cardiac Hypertrophy
| Article | Year |
|---|---|
[Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist].
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Disease Models, Animal; Fluvoxamine; Heart Ventricles; Male; Mice; Mice, Inbred ICR; Nitric Oxide Synthase Type III; Paroxetine; Proto-Oncogene Proteins c-akt; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sigma-1 Receptor; Signal Transduction | 2012 |
2 other study(ies) available for paroxetine and Cardiac Hypertrophy
| Article | Year |
|---|---|
GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress.
Topics: Animals; Cardiomegaly; G-Protein-Coupled Receptor Kinase 2; Inflammasomes; Isoproterenol; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Paroxetine; Rats; RNA, Small Interfering | 2023 |
Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Catecholamines; Cytochrome P-450 CYP2D6 Inhibitors; Disease Models, Animal; G-Protein-Coupled Receptor Kinase 2; Gene Knockout Techniques; Hypertension; Paroxetine; Rats; Receptors, Adrenergic, beta-1; Signal Transduction | 2021 |